Investment
Features
FeesSafety
Academy
More
Pluang+

Compare IDEXX Laboratories, Inc. (IDXX) vs Phillips 66 (PSX) Price & Performance

IDEXX Laboratories, Inc.Trade
Phillips 66Trade

Price performance (Past 24H)

Key statistics

IDEXX Laboratories, Inc. vs Phillips 66 — how do they compare? IDEXX Laboratories, Inc. trades at $518.11 (market cap $40.43B), while Phillips 66 trades at $278.52 (market cap $112.36B). The key difference: Phillips 66 is far larger — about 2.8× IDEXX Laboratories, Inc.'s market cap, and Phillips 66 pays a 1.8% dividend while IDEXX Laboratories, Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold IDEXX Laboratories, Inc. for 46 Days and Phillips 66 for 62 Days on average.

IDXXPSX
Market Cap
$40.43B$112.36B
Volume
692,1642,374,751
Sector
HealthEnergy
52-Week High
$766.68$281.60
52-Week Low
$504.70$126.76
Typical Hold Time
46 Days62 Days
Enterprise Value
$41.32B$128.83B
Dividend Yield
—1.8%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

IDEXX Laboratories, Inc.

IDEXX Laboratories (IDXX) trades at $519.87, up 2.61% on the day, with a bearish technical signal from moving averages but strong fundamentals including a 25.03% net income margin and consistent earnings beats. Revenue grew to $4.3B in 2025, and the company recently acquired CoVetAI to enhance veterinary workflow intelligence, signaling strategic expansion.

The stock's outlook is supported by robust profitability and analyst consensus, but faces headwinds from technical weakness and potential market volatility. With a $665 price target implying significant upside, the primary risks include competitive pressures and execution of growth initiatives amid economic uncertainties.

Phillips 66

Phillips 66 (PSX) trades at $283.31, up 4.3% with strong technical momentum and bullish moving average signals. The stock shows solid fundamentals with a P/E of 16.07, ROE of 24.02%, and consistent earnings beats in recent quarters. Recent news highlights structural refining advantages and AI implementation for operational efficiency, while analyst consensus remains positive with 54% buy ratings.

PSX presents a compelling investment case with strong profitability metrics and positive earnings momentum, though investors face risks from volatile energy markets and potential policy changes affecting diesel exports. The current price sits near consensus targets, suggesting balanced near-term upside potential with structural refining strengths supporting long-term value.

Returns comparison

Trailing returns across standard periods

Investor sentiment on Pluang

What Pluang investors did over the last 30 days

IDXX

No sentiment data available yet.

PSX
100% Buy0% Sell
Avg holding period · 62 Days

About IDEXX Laboratories, Inc.

Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets about 38% of its revenue from outside the United States.

Read more on IDXX →

About Phillips 66

Phillips 66 is an independent refiner with 12 refineries that have a total crude throughput capacity of 2.0 million barrels per day, or mmb/d, after converting its 255 mb/d Alliance refinery to a terminal. The midstream segment comprises extensive transportation and NGL processing assets. It also includes its DCP Midstream joint venture, which holds 45 natural gas processing facilities, 11 NGL fractionation plants, and a natural gas pipeline system with 58,000 miles of pipeline. Its CPChem chemical joint venture operates facilities in the United States and the Middle East and primarily produces olefins and polyolefins.

Read more on PSX →